Management of ANCA associated vasculitis

Area of Science:

• Rheumatology
• Immunology
• Internal Medicine

Background:

• Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a severe condition impacting small to medium vessels, leading to significant morbidity and mortality.
• Treatment advancements over two decades have focused on optimizing remission induction and maintenance strategies.

Purpose of the Study:

• To review the evolution of AAV management over the past 20 years.
• To highlight key randomized controlled trials that have shaped current treatment paradigms.
• To identify future research needs for personalized AAV care.

Main Methods:

• Review of pivotal randomized controlled trials in AAV management.
• Analysis of contemporary treatment approaches including immunosuppressive therapies and biologics.
• Examination of outcomes data regarding patient survival and organ function.

Main Results:

• Modern AAV care minimizes exposure to cyclophosphamide and glucocorticoids.
• Rituximab is increasingly utilized for remission induction and maintenance.
• Less toxic alternatives like methotrexate and mycophenolate mofetil are considered for non-life-threatening manifestations.
• Improvements in renal and overall survival have been observed.

Conclusions:

• Current AAV management strategies have led to improved patient outcomes.
• Further comparative effectiveness trials are needed for diverse patient subgroups.
• Prospective studies on psychosocial interventions are essential for patient-reported outcomes.
• There is a need for greater guidance on personalizing AAV treatment plans for physicians.